Your browser doesn't support javascript.
loading
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].
De Angelis, C; Bruzzese, D; Bernardo, A; Baldini, E; Leo, L; Fabi, A; Gamucci, T; De Placido, P; Poggio, F; Russo, S; Forestieri, V; Lauria, R; De Santo, I; Caputo, R; Cianniello, D; Michelotti, A; Del Mastro, L; De Laurentiis, M; Giuliano, M; De Placido, S; Arpino, G.
Afiliação
  • De Angelis C; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
  • Bruzzese D; Department of Public Health, University of Naples "Federico II", Naples, Italy.
  • Bernardo A; Oncologia Medica, Fondazione S. Maugeri IRCCS, Pavia, Italy.
  • Baldini E; Department of Oncology, S. Luca Hospital, Lucca, Italy.
  • Leo L; Unit of Oncology, A.O.R.N. dei Colli, Napoli, Naples, Italy.
  • Fabi A; Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Gamucci T; Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
  • De Placido P; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
  • Poggio F; UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Russo S; Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
  • Forestieri V; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
  • Lauria R; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
  • De Santo I; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
  • Caputo R; Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
  • Cianniello D; Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
  • Michelotti A; Azienda Ospedaliera Universitaria Pisana, Ospedale Santa Chiara, Pisa, Italy.
  • Del Mastro L; UO Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; University of Genova, Dipartimento di Medicina Interna e Specialità Mediche (DIMI), Genova, Italy.
  • De Laurentiis M; Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
  • Giuliano M; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy. Electronic address: m.giuliano@unina.it.
  • De Placido S; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
  • Arpino G; Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
ESMO Open ; 6(2): 100097, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33926709
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article